Recent FDA Approvals for Atopic Dermatitis, with Jonathan Silverberg, MD, PhD, MPH

At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, TN, a presentation titled ‘Recent Approvals in [Atopic Dermatitis] Therapy’ was given to attendees to highlight decisions in the atopic dermatitis space by the US Food and Drug Administration (FDA).

One presenter of this talk on recent atopic dermatitis approvals by the FDA was Jonathan Silverberg, MD, PhD, MPH, professor of dermatology and director of clinical research at the George Washington University School of Medicine and Health Science. Silverberg spoke with HCPLive in a new Q&A interview on this topic and on related research. The interview is listed below:

HCPLive: In your talk ‘Recent Approvals in AD Therapy,’ what are some of the most notable takeaways regarding FDA approvals for atopic dermatitis covered in this session?

Silverberg: I just presented on recent atopic dermatitis approvals, particularly focusing on biologic and systemic therapies. We have 2 new therapies that were just approved in the past 12 months, which are nemolizumab and lebrikizumab as biologics. So I took a deep dive into both of those drugs and my own clinical pearls, as well as some thoughts about where and how to use them.

I also threw an update on data that we have now or recent data that we have for dupilumab as well as the oral JAK inhibitors, because we've had a lot of new insights, even though, technically, they're a little bit older therapies.

HCPLive: With upcoming therapeutic research in atopic dermatitis, are there any drugs not approved yet which you are looking forward to?

Silverberg: Yeah, the pipeline for atopic dermatitis therapies is enormous right now, and it's really cool. There's a lot of stuff being tested with a lot of novel technologies. I think long-term, the bispecifics or multi-specific biologics are really cool. The ability to hit multiple targets simultaneously [is great], but without the off-target effects.

We're seeing all kinds of novel pathways being probed in atopic dermatitis, OX40 and 40 ligand, interleukin-18, interleukin-22 receptor. And we're not sure where all these are going to go. But these are really exciting and pushing the boundaries of science and the disease.

HCPLive: Outside of atopic dermatitis, what are you looking forward to in terms of dermatology research?

Silverberg: I think there's a tremendous need, outside of atopic dermatitis and broadly-speaking within dermatology, for better diagnostics and better biomarkers. I think our classification system that we use in dermatology, while over 100 years old, and while we have great, skilled clinical dermatologists doing it, really needs to be brought into the modern era. We really need to have better prognostic tools, theranostic tools, and diagnostic tools across the variety of our different immune mediated diseases and just chronic inflammatory skin disorders.

HCPLive: You are the founder of RAD. What message would you share with colleagues, clinicians, and attendees?

Silverberg: RAD was created to address this amazing increase in knowledge and treatment options that we have now for atopic dermatitis. It's hard for the clinician who's busy in the trenches to keep up with all the data and to really gain insights into all these new therapies that kind of hit us at once and are still coming really fast and furious.

How do we where should we use them? When should we use them? How do we keep up with all that? RAD is here to provide both cutting edge perspectives as well as that evidence-based approach, knowing that you're getting the top quality information all in a one-stop shop.

To find out more from Silverberg and other experts in the field of dermatology, view our latest conference coverage.

The quotes used in this Q&A interview were edited for the purposes of clarity.